CG Oncology posts Q2 2025 results update

CG Oncology, Inc. filed a current report to note that it issued a press release on August 8, 2025 announcing its financial results for the quarter ended June 30, 2025.

Accepted by SEC EDGAR 08/08/2025 - 08:15 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

CG Oncology, Inc. filed a current report to note that it issued a press release on August 8, 2025 announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1, meaning it is provided for informational purposes and is not treated as filed for liability purposes under the Exchange Act. The company’s common stock continues to trade on the Nasdaq Global Select Market under the symbol CGON.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CG Oncology (CGON) disclose in this 8-K filing?

CG Oncology reported that it issued a press release on August 8, 2025 announcing its financial results for the quarter ended June 30, 2025, and furnished that release as Exhibit 99.1.

Which period’s results does CG Oncology’s latest press release cover?

The press release announced by CG Oncology covers its financial results for the quarter ended June 30, 2025.

How are the CG Oncology Q2 2025 results treated in this 8-K?

The results are included through a furnished press release under Item 2.02, and the company specifies that this information, including Exhibit 99.1, is not deemed "filed" for purposes of Section 18 of the Exchange Act.

Where can investors find CG Oncology’s Q2 2025 financial details?

Investors can review the detailed financial information in the press release attached as Exhibit 99.1 to this 8-K current report.

On which exchange is CG Oncology’s common stock listed and under what symbol?

CG Oncology’s common stock is listed on The Nasdaq Global Select Market under the trading symbol CGON.

Who signed the CG Oncology August 8, 2025 8-K report?

The report was signed on behalf of CG Oncology, Inc. by Josh Patterson, who is the General Counsel and Chief Compliance Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false000199179200019917922025-08-082025-08-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 08, 2025

CG Oncology, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41925	37-1611499
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
400 Spectrum Center Drive Suite 2040
Irvine, California				92618
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (949) 409-3700

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CGON		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 8, 2025, CG Oncology, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release, dated August 8, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CG Oncology, Inc.
Date: August 8, 2025	By: /s/ Josh Patterson
	Name: Josh Patterson
	Title: General Counsel and Chief Compliance Officer